NAD+

Also known as · Nicotinamide adenine dinucleotide · Nadide · Coenzyme I

Form
Lyophilized powder
Purity
≥98% (HPLC)
Molecular formula
C21H27N7O14P2
Molecular weight
663.4 g/mol
CAS number
53-84-9
Sequence
Dinucleotide coenzyme (not a peptide)
COA
Available on request

In stock

Request pricing

Contact us for current pricing and bulk quotes.

Reserve vial →

For research use only. Not for human consumption. Buyers must be affiliated with a research institution.

01 / Research summary

What the literature reports

NAD+ is not a peptide — it is a pyridine dinucleotide coenzyme, made of nicotinamide mononucleotide joined to adenosine monophosphate through a pyrophosphate bridge. It is one of the most abundant cofactors in every living cell.

Cellaire classifies exogenous NAD+ as limited human evidence. A review by Xie et al. (Signal Transduct Target Ther 2020) catalogs NAD+ roles in redox homeostasis, sirtuin and PARP activity, and mitochondrial function, and links deficiency to metabolic disease, aging, and neurodegeneration — but human clinical evidence for injectable or infused NAD+ remains sparse.

02 / Reconstitution

Reconstitution reference

Illustrative unit math for a 500 mg vial reconstituted with 5 mL bacteriostatic water. This is not a dose recommendation.

Vial500 mg
BAC water5 mL
Concentration100 mg/mL
Example unit math50 mg
On a U-100 syringe50 units on U-100
Open the reconstitution calculator →

03 / Overview

Molecular overview

NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a dinucleotide made of two nucleotides joined by a pyrophosphate bridge: nicotinamide mononucleotide on one end, adenosine monophosphate on the other.

It is a redox cofactor for hundreds of enzymes (dehydrogenases), a substrate for sirtuins, PARPs, CD38, and SARM1, and a signaling molecule regulating energy metabolism and circadian biology.

Cellular NAD+ is regenerated primarily through the salvage pathway (NAMPT-mediated) and to a smaller extent through the de novo pathway from tryptophan. Bulk supplementation with NAD+ precursors (NR, NMN) has been studied more extensively than injectable NAD+ itself.

Injectable NAD+ is used off-label in some clinical settings but is not FDA-approved for any indication.

04 / References

References

  1. PubChem — NAD+ (CID 5892) ↗
  2. Xie N et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020 ↗